11月14日，誉衡药业盘中上涨2.03%，截至10:09，报3.51元/股，成交1.29亿元，换手率1.76%，总市值 78.83亿元。 资金流向方面，主力资金净流出579.95万元，特大单买入946.17万元，占比7.36%，卖出1497.89万元， 占比11.65%；大单买入2507.17万元，占比19.50%，卖出2535.40万元，占比19.72%。 机构持仓方面，截止2025年9月30日，誉衡药业十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股6636.97万股，相比上期增加3513.66万股。 责任编辑：小浪快报 截至11月10日，誉衡药业股东户数10.48万，较上期减少0.66%；人均流通股20038股，较上期增加 0.85%。2025年1月-9月，誉衡药业实现营业收入16.65亿元，同比减少10.36%；归母净利润2.44亿元，同 比增长32.85%。 分红方面，誉衡药业A股上市后累计派现6.92亿元。近三年，累计派现0.00元。 誉衡药业今年以来股价涨40.96%，近5个交易日涨4.46%，近20日涨8.00%，近60日跌6.40%。 资料显示，哈尔滨誉衡药业股份有限公司位于北 ...

资料显示，哈尔滨誉衡药业股份有限公司位于北京市顺义区空港开发区B区裕华路融慧园28号楼，成立 日期2000年3月27日，上市日期2010年6月23日，公司主营业务涉及药品生产和药品代理销售。主营业务 收入构成为：维生素类药物43.88%，心脑血管药物28.00%，骨科药物10.72%，电解质类药物8.25%，抗 肿瘤药物3.79%，其他用药领域3.56%，抗感染药物1.58%，其他(补充)0.22%。 截至10月20日，誉衡药业股东户数10.55万，较上期增加2.88%；人均流通股19869股，较上期减少 2.80%。2025年1月-9月，誉衡药业实现营业收入16.65亿元，同比减少10.36%；归母净利润2.44亿元，同 比增长32.85%。 11月11日，誉衡药业涨0.00%，成交额1.48亿元。两融数据显示，当日誉衡药业获融资买入额1570.19万 元，融资偿还1654.92万元，融资净买入-84.73万元。截至11月11日，誉衡药业融资融券余额合计3.71亿 元。 融资方面，誉衡药业当日融资买入1570.19万元。当前融资余额3.71亿元，占流通市值的4.94%，融资余 额超过近一年60%分位水平，处 ...

Core Insights - On October 23, Yuheng Pharmaceutical experienced a decline of 1.53% with a trading volume of 137 million yuan, indicating a negative market sentiment towards the company [1] - The company reported a financing net buy of -3.40 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 23, the total margin balance for Yuheng Pharmaceutical stood at 380 million yuan, which is 5.37% of its circulating market value, indicating a relatively high leverage position [1] Financing and Margin Data - On October 23, the financing buy amount was 14.50 million yuan, while the financing repayment was 17.90 million yuan, leading to a net financing outflow [1] - The current financing balance of 380 million yuan exceeds the 70th percentile level over the past year, indicating a significant level of borrowing [1] - In terms of securities lending, there were no shares sold on October 23, with a total of 0 shares in the lending balance, which is at the 80th percentile level over the past year [1] Company Financial Performance - As of September 19, the number of shareholders for Yuheng Pharmaceutical was 105,700, a decrease of 1.03% from the previous period, while the average circulating shares per person increased by 1.04% to 19,831 shares [2] - For the first half of 2025, the company reported a revenue of 1.10 billion yuan, a year-on-year decrease of 9.97%, while the net profit attributable to shareholders was 134 million yuan, reflecting a year-on-year increase of 7.56% [2] Dividend and Shareholding Information - Since its A-share listing, Yuheng Pharmaceutical has distributed a total of 692 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 31.23 million shares as a new shareholder [3]

Core Insights - On September 30, Yuheng Pharmaceutical experienced a decline of 0.96% with a trading volume of 106 million yuan, indicating a challenging market environment [1] - The company reported a net financing outflow of 13.63 million yuan on the same day, with a total financing and securities balance of 389 million yuan, which is 5.74% of its market capitalization [1] - As of September 19, the number of shareholders decreased by 1.03% to 105,700, while the average circulating shares per person increased by 1.04% to 19,831 shares [2] Financial Performance - For the first half of 2025, Yuheng Pharmaceutical achieved a revenue of 1.1 billion yuan, reflecting a year-on-year decrease of 9.97%, while the net profit attributable to shareholders increased by 7.56% to 134 million yuan [2] - Cumulatively, the company has distributed 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholding Structure - As of June 30, 2025, Hong Kong Central Clearing Limited emerged as the fourth largest circulating shareholder, holding 31.23 million shares as a new investor [3]

Core Insights - On September 24, Yuheng Pharmaceutical's stock increased by 0.31%, with a trading volume of 130 million yuan [1] - The company reported a financing buy-in of 10.47 million yuan and a financing repayment of 11.27 million yuan, resulting in a net financing outflow of 799,100 yuan [1] - As of September 24, the total margin balance for Yuheng Pharmaceutical was 409 million yuan, representing 5.81% of its market capitalization [1] Financing Overview - On the same day, the financing buy-in was 10.47 million yuan, with a current financing balance of 409 million yuan, which is above the 80th percentile level over the past year [1] - In terms of securities lending, there were no shares repaid or sold on September 24, with a remaining loan balance of 321 yuan, also exceeding the 80th percentile level over the past year [1] Company Performance - As of September 19, the number of shareholders for Yuheng Pharmaceutical was 105,700, a decrease of 1.03% from the previous period [2] - For the first half of 2025, the company reported a revenue of 1.1 billion yuan, a year-on-year decrease of 9.97%, while the net profit attributable to shareholders was 134 million yuan, reflecting a year-on-year increase of 7.56% [2] Dividend History - Since its A-share listing, Yuheng Pharmaceutical has distributed a total of 692 million yuan in dividends, with no dividends paid in the last three years [3] Shareholding Structure - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest shareholder among the top ten circulating shareholders, holding 31.23 million shares as a new investor [3]